Premium
INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE
Author(s) -
Ansell S.M.,
Bartlett N.L.,
Chen R.W.,
Herrera A.,
DomingoDomenech E.,
Mehta A.,
ForeroTorres A.,
GarciaSanz R.,
Armand P.,
Devata S.,
Rodriguez Izquierdo A.,
Lossos I.S.,
Reeder C.B.,
Sher T.,
ChoeJuliak C.,
Prier K.,
Schwarz S.E.,
Strassz A.,
Alland L.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.134_2629
Subject(s) - brentuximab vedotin , medicine , pembrolizumab , tolerability , oncology , refractory (planetary science) , cohort , anaplastic large cell lymphoma , gastroenterology , lymphoma , surgery , adverse effect , cd30 , immunotherapy , cancer , physics , astrobiology